Filed: 2/13/2025ACC: 0000950123-25-002049
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 11 equity positions with a total reported market value of $410.08M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
11
Positions
$410.08M
Total AUM (reported)
27.93M
Total Shares
Allocation by class
COMMON STOCK$363.83M88.7%
COMMON SHARES$46.26M11.3%
Portfolio Concentration
Top 3$263.59M64.3%
4–10$142.34M34.7%
11–25$4.16M1.0%
Top 3 weight
64.3%
Top 10 weight
99.0%
Voting Authority Distribution
Total shares with voting rights: 27.93M
Sole
Full voting authority
27.93M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole11
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings11
Rows:
Arcellx, Inc.
SOLEShares2.35M
TypeSH
Market value$179.96M
43.88%
Sole
2.35M
Shared
0.00
None
0.00
ARS Pharmaceuticals, Inc.
SOLEShares4.01M
TypeSH
Market value$42.34M
10.32%
Sole
4.01M
Shared
0.00
None
0.00
CRISPR Therapeutics AG
SOLEShares1.05M
TypeSH
Market value$41.29M
10.07%
Sole
1.05M
Shared
0.00
None
0.00
Design Therapeutics, Inc.
SOLEShares6.53M
TypeSH
Market value$40.27M
9.82%
Sole
6.53M
Shared
0.00
None
0.00
Zenas BioPharma, Inc
SOLEShares4.91M
TypeSH
Market value$40.23M
9.81%
Sole
4.91M
Shared
0.00
None
0.00
Mineralys Therapeutics Inc.
SOLEShares2.02M
TypeSH
Market value$24.83M
6.05%
Sole
2.02M
Shared
0.00
None
0.00
Alumis Inc.
SOLEShares1.96M
TypeSH
Market value$15.40M
3.76%
Sole
1.96M
Shared
0.00
None
0.00
Oruka Therapeutics, Inc
SOLEShares430.33K
TypeSH
Market value$8.34M
2.03%
Sole
430.33K
Shared
0.00
None
0.00
Nkarta, Inc.
SOLEShares3.33M
TypeSH
Market value$8.30M
2.02%
Sole
3.33M
Shared
0.00
None
0.00
enGene Holdings Inc.
SOLEShares747.75K
TypeSH
Market value$4.97M
1.21%
Sole
747.75K
Shared
0.00
None
0.00
KALA Bio, Inc.
SOLEShares598.94K
TypeSH
Market value$4.16M
1.01%
Sole
598.94K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Arcellx, Inc.SOLE | Common Stock | 2.35M | SH | $179.96M 43.88% | 2.35M | 0.00 | 0.00 |
ARS Pharmaceuticals, Inc.SOLE | Common Stock | 4.01M | SH | $42.34M 10.32% | 4.01M | 0.00 | 0.00 |
CRISPR Therapeutics AGSOLE | Common Shares | 1.05M | SH | $41.29M 10.07% | 1.05M | 0.00 | 0.00 |
Design Therapeutics, Inc.SOLE | Common Stock | 6.53M | SH | $40.27M 9.82% | 6.53M | 0.00 | 0.00 |
Zenas BioPharma, IncSOLE | Common Stock | 4.91M | SH | $40.23M 9.81% | 4.91M | 0.00 | 0.00 |
Mineralys Therapeutics Inc.SOLE | Common Stock | 2.02M | SH | $24.83M 6.05% | 2.02M | 0.00 | 0.00 |
Alumis Inc.SOLE | Common Stock | 1.96M | SH | $15.40M 3.76% | 1.96M | 0.00 | 0.00 |
Oruka Therapeutics, IncSOLE | Common Stock | 430.33K | SH | $8.34M 2.03% | 430.33K | 0.00 | 0.00 |
Nkarta, Inc.SOLE | Common Stock | 3.33M | SH | $8.30M 2.02% | 3.33M | 0.00 | 0.00 |
enGene Holdings Inc.SOLE | Common Shares | 747.75K | SH | $4.97M 1.21% | 747.75K | 0.00 | 0.00 |
KALA Bio, Inc.SOLE | Common Stock | 598.94K | SH | $4.16M 1.01% | 598.94K | 0.00 | 0.00 |